Tanaproget

Tanaproget is a nonsteroidal selective progesterone receptor modulator (SPRM) that was under development by Tanabe Seiyaku and later TAP Pharmaceutical Products for use in hormone replacement therapy (HRT) and as a contraceptive. However, development of the drug was discontinued and it was never marketed.

Pharmacology

Tanaproget has high affinity for the progesterone receptor (PR) and is a potent and selective agonist of the PR. It is nonsteroidal and, unlike progestogens, does not have off-target hormonal activity, such as androgen, glucocorticoid, or mineralocorticoid activity. This may result in fewer side effects and improved tolerability relative to progestogens.

Clinical development

Tanaproget was under development for use in HRT and as a contraceptive and reached phase II clinical trials for these indications. However, development was discontinued, reportedly due to poor bioavailability and the need for high doses.

See also

• List of investigational sex-hormonal agents
• List of selective progesterone receptor modulators